Search

Displaying results 2301 - 2310 of 7498 in total
  1. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. … It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.

  2. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence … [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.

  3. Drug

    Ethanolamine oleate

    go.drugbank.com/drugs/DB06689
    Approved

    It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

  4. Drug

    Tenoxicam

    go.drugbank.com/drugs/DB00469
    ApprovedInvestigational

    Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  5. Drug

    Sodium ferric gluconate complex

    go.drugbank.com/drugs/DB09517
    Approved

    It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate. … The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons on gel chromatography.

  6. Drug

    Vecuronium

    go.drugbank.com/drugs/DB01339
    ApprovedInvestigational

    A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. … alternatives to, other established neuromuscular blocking agents.

  7. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. … [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.

  8. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

    Synonyms: Co-ArgI-PEG, Co-ArgI-PEG modified human arginase I
  9. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.

  10. Drug

    Gadobutrol

    go.drugbank.com/drugs/DB06703
    ApprovedInvestigational

    Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. … of NSF thanks to the macrocyclic structures that limit dechelation of gadolinium.